SICKLE CELL STUDIES

Etavopivat is the first in a new class of drugs substantially reduces vaso-occlusive crisis events and improving haemoglobin response in sickle cell disease

Phase 3 results showed a 27% reduction in VOC events, delayed time to first VOC, and improvements in hemoglobin.